NREP
NEW REPRESENTATIVE AT IB RECEIVED
03/12/2026
Back to search
Official data from USPTO
LCA PHARMACEUTICAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
37
Latest update
03/13/2026
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
10/07/2016
Registration date
03/13/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/27/2024
Last transaction
03/13/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
33
Owner location
FR
Examiner
TWOHIG, SHANNON MARIE
Law office
N30
Current location
TMO LAW OFFICE 121
Mark description
The mark consists of the stylized letters "LCA" in white above the stylized word "PHARMACEUTICAL" in white. The wording appears superimposed over a blue background and blue globe design.
Holders and representatives
Holders
LABORATOIRE DE CONTACTOLOGIE APPLIQUEE - LCA,
Representatives
Leigh Ann Lindquist Sughrue Mion, PLLC
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical productspreparations for the treatment of osteoarthritis and other joint diseases; preparations for the treatment of pain and joint diseasesparticularly osteoarthritis; injectable preparations for use in rheumatologypresented in the form of pre-filled disposable sterile syringes; preparations for dermatological use for filling in face wrinkles; pharmaceutical preparations for dermatological use; injectable preparations for dermatological use presented in the form of sterile pre-filled disposable syringes; Sterileisotonic and preservative-free single doses for symptomatic treatments of eye irritations and for nose and eye care
Class 10
Surgical and medical apparatus and instrumentssterile single use instrumentation for cataract surgery; Medical devices for intracorporal injectionlenses in the nature of intraocular prostheses for surgical implantation packed in an injector; medical devices for intracorporeal injection; medical devices for intracorporeal injection consisting of a disposable sterile syringe; artificial implantsnamely introcular implants; sterile intraocular implants of artificial material and medical devices for use in cataract surgery
Class 42
Pharmaceutical research services; medical research services; scientific data analysis services; chemical analyses; chemical research; medical data analysis services; scientific research services for medical purposesparticularly design and development of implantable medical devices for use in ophthalmologyrheumatology and dermatology
Class 44
Medical services; medical assistance; health counseling services; pharmacy advicemedical advice related to pharmaceuticals; health care for human beings; advisory services and medical services in the field of rheumatology and dermatology; hygiene and beauty care; all the aforementioned services not in the field of ophthalmology
Publications
History of USPTO decisions and trademark events.
37 publications found
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
10/24/2025
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
10/02/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
10/02/2025
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
05/27/2025
C71T
CANCELLED SECTION 71
09/27/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/13/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/24/2018
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
06/20/2018
XXCR
GENERIC MADRID TRANSACTION CREATED
06/20/2018
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/13/2018
R.PR
REGISTERED-PRINCIPAL REGISTER
03/13/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/26/2017
PUBO
PUBLISHED FOR OPPOSITION
12/26/2017
GPNX
NOTIFICATION PROCESSED BY IB
12/22/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/06/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/06/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
12/06/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/14/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
11/14/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/14/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
11/14/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/14/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/21/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/21/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/21/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/20/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/20/2017
RFNT
REFUSAL PROCESSED BY IB
04/09/2017
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/21/2017
RFRR
REFUSAL PROCESSED BY MPU
03/21/2017
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/21/2017
MAFR
APPLICATION FILING RECEIPT MAILED
03/21/2017
CNRT
NON-FINAL ACTION WRITTEN
03/20/2017
DOCK
ASSIGNED TO EXAMINER
03/17/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/17/2017
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/16/2017
Continuous trademark protection
Get notified about every new filing that threatens LCA PHARMACEUTICAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.